In order to assist the informed decision-making process on TKI selection for NSCLC treatment, the present study aimed to compare the EGFR mutation-guided use of afatinib, erlotinib, and gefitinib versus empirical chemotherapy for first-line treatment of advanced NSCLC in the public healthcare setting of Hong Kong. This evidence concerns the gene EGFR and non-small cell lung carcinoma.